Dr Anne Mackie, Director of PHE Screening, explains how inequalities affect screening and what actions we are taking to understand and address these differences.
public information and informed choice
As part of a wider investigation into why women are tested late, we commissioned the UK Thalassaemia Society (UKTS) and Sickle Cell Society (SCS) to carry out face to face interviews with women and couples who had recent experience of the SCT programme.
When you take consent for newborn blood spot (NBS) screening, you need to know about residual blood spots and be able to talk to parents about them. This blog will help you do this.
I’m the Sickle Cell and Thalassaemia Screening Lead at Northampton General Hospital and Kettering General Hospital. For the past year I’ve been on secondment as national project lead for the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme.
The UK National Screening Committee (UKNSC) is consulting on its guidance covering the development, production and review of information to support all UK population screening programmes.
NHS England has published the 2017-18 service specifications for all 11 NHS Screening Programmes. The specifications accompany the 2017-18 agreement that outlines how NHS England commissions certain public health services under section 7A of the National Health Service Act 2006.
Today we’ve published our latest easy read information leaflet to help ensure screening is accessible to individuals with learning disabilities and low literacy levels.
We’ve updated our antenatal and newborn screening information for public and professionals following a change to the vaccination schedule for babies.
Back in November 2016 and March 2017 we published blog articles about the additional option of non-invasive prenatal testing (NIPT) to the fetal anomaly screening pathway.
It's really important that NHS services listen to the people who actually use them - patients and members of the public. Otherwise we could end up with services that look great on paper but...